NZ628130A - Treatment of addiction and impulse-control disorders using pde7 inhibitors - Google Patents

Treatment of addiction and impulse-control disorders using pde7 inhibitors

Info

Publication number
NZ628130A
NZ628130A NZ628130A NZ62813013A NZ628130A NZ 628130 A NZ628130 A NZ 628130A NZ 628130 A NZ628130 A NZ 628130A NZ 62813013 A NZ62813013 A NZ 62813013A NZ 628130 A NZ628130 A NZ 628130A
Authority
NZ
New Zealand
Prior art keywords
addiction
impulse
treatment
control disorders
pde7 inhibitors
Prior art date
Application number
NZ628130A
Other languages
English (en)
Inventor
George A Gaitanaris
Gregory A Demopulos
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Priority claimed from PCT/US2013/039866 external-priority patent/WO2013176877A2/en
Publication of NZ628130A publication Critical patent/NZ628130A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ628130A 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors NZ628130A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
NZ628130A true NZ628130A (en) 2017-02-24

Family

ID=55442549

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628130A NZ628130A (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Country Status (11)

Country Link
JP (4) JP2016138137A (pt)
CY (1) CY1121275T1 (pt)
DK (1) DK2846805T3 (pt)
ES (1) ES2711949T3 (pt)
HK (1) HK1208373A1 (pt)
HR (1) HRP20190279T1 (pt)
HU (1) HUE043518T2 (pt)
LT (1) LT2846805T (pt)
NZ (1) NZ628130A (pt)
PT (1) PT2846805T (pt)
RU (1) RU2665134C2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027157A1 (ja) 2021-08-27 2023-03-02 住友金属鉱山株式会社 赤外線硬化型インク組成物、赤外線硬化物、赤外線硬化物の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US7915285B2 (en) * 2005-09-26 2011-03-29 The Regents Of The University Of Colorado Method for treating drug and behavioral addictions
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2684059C (en) * 2007-04-11 2016-07-12 Omeros Corporation Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions

Also Published As

Publication number Publication date
PT2846805T (pt) 2019-02-27
HK1208373A1 (en) 2016-03-04
RU2014149192A (ru) 2016-07-10
JP2016138137A (ja) 2016-08-04
LT2846805T (lt) 2019-02-25
JP2019142980A (ja) 2019-08-29
ES2711949T3 (es) 2019-05-08
HUE043518T2 (hu) 2019-08-28
HRP20190279T1 (hr) 2019-04-05
DK2846805T3 (en) 2019-03-18
CY1121275T1 (el) 2020-05-29
RU2665134C2 (ru) 2018-08-28
JP2017171691A (ja) 2017-09-28
JP6963431B2 (ja) 2021-11-10
JP2021138766A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
EP4275752A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX2016000173A (es) Sistemas y metodos para seguimiento y presentacion de datos de terapia para acufenos.
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
PE20150020A1 (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2014011838A (es) Uso de neuregulina para tratar lesion de nervio periferico.
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
WO2013176877A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
MX346339B (es) (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.
NZ628130A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
GB201115977D0 (en) Neurodevelopmental disorders
WO2014045126A3 (en) Treatment of pain by inhibition of usp5 de-ubiquitinase
TN2015000236A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
UA69428U (ru) Способ лечения больных диабетической ретинопатией
UA61823U (ru) Применение гамма-оксимасляной кислоты как стимулятора ускорения скорости регенерации и восстановления силы мышечных сокращений

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3103871, OMEROS CORPORATION, 201 ELLIOTT AVENUE WEST, SEATTLE, WASHINGTON 98119, US

Effective date: 20150312

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20170701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417